Physician profile
Christopher Mulloney
NPI 1255005872
$94,829.37
in general payments reported to CMS, 2019-2025
8 companies · $6,100 in 2025
The $6,100 reported for 2025 was more than what 99% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $96.36 · 2022: $216 · 2023: $49K · 2024: $40K · 2025: $6,100.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $76K · Travel and Lodging: $15K · Food and Beverage: $3,021.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $76,330.50 |
| Travel and Lodging | $15,165.51 |
| Food and Beverage | $3,021.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $91,124.44 | 2022-2025 | |
| Indivior INC. | $3,134.37 | 2022-2025 | Sublocade |
| Otsuka America Pharmaceutical, INC. | $193.65 | 2023-2024 | Rexulti, Abilify Maintena |
| Vanda Pharmaceuticals INC. | $142.11 | 2024 | Fanapt |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $96.64 | 2022-2023 | |
| Teva Pharmaceuticals USA, INC. | $62.02 | 2021 | |
| Uswm, LLC | $41.80 | 2023 | Zimhi, Lucemyra |
| Sunovion Pharmaceuticals INC. | $34.34 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Mulloney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.